A groundbreaking study from the University of California, Irvine unveils a transformative approach to treating Alzheimer’s disease and other neurological disorders: reprogrammed human microglia that act as living delivery vehicles for targeted therapies inside the brain.

Published in Cell Stem Cell, the research introduces an innovative strategy to bypass the blood-brain barrier—a long-standing obstacle in brain medicine—by leveraging microglia, the brain’s native immune cells, as programmable couriers that detect disease and act directly at the source.

Smart Cells that Deliver Where Drugs Can’t

The team, supported by the National Institutes of Health and other major organizations, used induced pluripotent stem cells (iPSCs) to create human microglia and then genetically engineered them using CRISPR technology. These enhanced microglia were programmed to secrete neprilysin, an enzyme capable of breaking down toxic beta-amyloid plaques—a hallmark of Alzheimer’s pathology.

Crucially, the cells only activated this enzyme near the amyloid plaques, thanks to a built-in plaque-sensitive promoter, ensuring that the therapy was both highly targeted and self-regulating.

Results That Redefine Brain Treatment

In Alzheimer’s mouse models, these programmable microglia led to:

• Reduced amyloid plaque burden

• Preserved neurons and synapses

• Decreased neuroinflammation

• Lowered blood biomarkers of brain damage

Even more strikingly, local transplantation of microglia into select brain regions yielded beneficial effects across the entire brain, suggesting that this therapy doesn’t just work—it scales within the neural environment.

A Platform for Neurological Precision Medicine

The researchers also tested the approach in models of brain cancer and multiple sclerosis, where engineered microglia showed disease-specific responses. This flexibility hints at the potential of the platform to be tailored for a wide range of central nervous system conditions—not just Alzheimer’s.

“This work opens the door to a completely new class of brain therapies,” said study co-author Prof. Robert Spitale. “Instead of relying on synthetic drugs or gene therapy vectors, we’re using the brain’s own immune system as a programmable delivery tool.”

What Comes Next

While the findings are promising, several steps remain before this becomes a clinical option. These include validating long-term safety, refining manufacturing methods, and eventually conducting human trials. However, since the microglia are derived from patient-specific iPSCs, future treatments could be personalized, reducing the risk of immune rejection.

This pioneering work was led by Prof. Mathew Blurton-Jones and included contributions from Jean Paul Chadarevian, Alina Chadarevian, Jonathan Hasselmann, Hayk Davtyan, and others at UC Irvine’s Department of Neurobiology & Behavior, Sue & Bill Gross Stem Cell Research Center, and the Institute for Memory Impairments and Neurological Disorders.

Source:
Chadarevian, J.P., Blurton-Jones, M., Spitale, R. et al. (2025). Programmable iPSC-derived microglia enable brain-targeted protein delivery and neuropathology reduction in Alzheimer’s models. Cell Stem Cell. https://doi.org/10.1016/j.stem.2024.12.006